Goldman Sachs’s Inhibrx, Inc. Common Stock INBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-376,540
| Closed | -$13.2M | – | 5051 |
|
|
2024
Q1 | $13.2M | Buy |
376,540
+223,360
| +146% | +$7.81M | ﹤0.01% | 1850 |
|
|
2023
Q4 | $5.82M | Sell |
153,180
-6,289
| -4% | -$239K | ﹤0.01% | 2487 |
|
|
2023
Q3 | $2.93M | Sell |
159,469
-90,948
| -36% | -$1.67M | ﹤0.01% | 2845 |
|
|
2023
Q2 | $6.5M | Buy |
250,417
+75,236
| +43% | +$1.95M | ﹤0.01% | 2374 |
|
|
2023
Q1 | $3.31M | Buy |
175,181
+2,961
| +2% | +$55.9K | ﹤0.01% | 2851 |
|
|
2022
Q4 | $4.24M | Buy |
172,220
+16,916
| +11% | +$417K | ﹤0.01% | 2742 |
|
|
2022
Q3 | $2.79M | Buy |
155,304
+74,857
| +93% | +$1.34M | ﹤0.01% | 3102 |
|
|
2022
Q2 | $914K | Sell |
80,447
-64,032
| -44% | -$728K | ﹤0.01% | 4008 |
|
|
2022
Q1 | $3.22M | Buy |
144,479
+22,413
| +18% | +$499K | ﹤0.01% | 3170 |
|
|
2021
Q4 | $5.33M | Sell |
122,066
-42,467
| -26% | -$1.85M | ﹤0.01% | 2750 |
|
|
2021
Q3 | $5.48M | Buy |
164,533
+112,951
| +219% | +$3.76M | ﹤0.01% | 2730 |
|
|
2021
Q2 | $1.42M | Buy |
51,582
+8,998
| +21% | +$248K | ﹤0.01% | 3773 |
|
|
2021
Q1 | $855K | Buy |
42,584
+30,067
| +240% | +$604K | ﹤0.01% | 4016 |
|
|
2020
Q4 | $413K | Sell |
12,517
-77,213
| -86% | -$2.55M | ﹤0.01% | 3927 |
|
|
2020
Q3 | $1.62M | Buy |
+89,730
| New | +$1.62M | ﹤0.01% | 3024 |
|